Evotec SE (NASDAQ:EVO - Get Free Report) shares saw an uptick in trading volume on Friday . 385,764 shares were traded during mid-day trading, an increase of 192% from the previous session's volume of 132,151 shares.The stock last traded at $4.40 and had previously closed at $5.35.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Evotec in a report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft lowered Evotec from a "hold" rating to a "sell" rating in a report on Thursday, August 8th. Morgan Stanley lowered Evotec from an "overweight" rating to an "equal weight" rating and dropped their price target for the company from $15.00 to $6.00 in a research report on Monday, July 29th. Finally, Jefferies Financial Group lowered Evotec from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $8.70 to $3.80 in a research report on Monday, October 7th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $5.93.
View Our Latest Analysis on EVO
Evotec Price Performance
The company has a quick ratio of 1.99, a current ratio of 2.09 and a debt-to-equity ratio of 0.43. The company has a 50 day moving average of $3.83 and a 200 day moving average of $4.20.
Hedge Funds Weigh In On Evotec
Several institutional investors have recently bought and sold shares of the stock. Novo Holdings A S bought a new position in shares of Evotec in the 2nd quarter valued at approximately $71,183,000. Cetera Advisors LLC acquired a new stake in shares of Evotec in the first quarter worth $188,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Evotec in the second quarter worth $87,000. DCF Advisers LLC grew its stake in Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock valued at $552,000 after buying an additional 67,156 shares during the last quarter. Finally, Mediolanum International Funds Ltd bought a new position in Evotec in the 3rd quarter worth $512,000. 5.81% of the stock is currently owned by institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
